Han, M. K., Antila, M., Ficker, J. H., Gordeev, I., Guerreros, A., Bernus, A. L., Roquilly, A., Sifuentes-Osornio, J., Tabak, F., Teijeiro, R., Bandelli, L., Bonagura, D. S., Shu, X., Felser, J. M., Knorr, B., Cao, W., Langmuir, P., Lehmann, T., Levine, M., & Savic, S. (2022). ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 4, e351–e361. http://access.bl.uk/ark:/81055/vdc_100153808864.0x000002